

MANAGEMENT

Stephen Roth, Ph.D.
President and CEO

Eric Sandquist
Chief Business Officer

David Zopf, M.D.
Chief Scientific Officer

Nancy Jean Barnabei
Chief Financial Officer

Elliot Morales, Jr.
Vice President, Operations

Clayton A. Buck, Ph.D.
Director, R & D

BOARD OF DIRECTORS

Stephen Roth, Ph.D.
President and CEO

Patrick Gage, Ph.D.

Brian Halak, Ph.D.
Partner, Domain Associates

Hyman Kahn, M.D.

Zev Scherl
*General Partner,
NewSpring Capital*

Geeta Vemuri, Ph.D.
Partner, Quaker BioVentures

ADVISORS

Douglas S. McNair,
M.D., Ph.D.
Clinical Affairs Consultant

Scott Rakestraw, Ph.D.
Senior Business Advisor

Bruce A. Silver,
M.D., FACP
Medical Monitor

ABOUT IMMUNE CONTROL

Immune Control is an emerging pharmaceutical company developing novel, orally-available, small molecules for autoimmune/inflammatory diseases.

The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. We have also uncovered first-in-class mechanisms involving the selective modulation of peripheral serotonin receptors that are highly relevant to autoimmune/inflammatory disease. Immune Control is applying these discoveries to treating autoimmune/inflammatory diseases, hematologic cancer, and organ transplant rejection.


OUR TECHNOLOGY

Immune Control is a leader in the emerging field of serotonin-based immunotherapeutics.

Our preclinical development program has yielded important insights into the design of orally-available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, we are conducting phase I, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist.

EXPERIENCED MANAGEMENT TEAM

Stephen Roth, Ph.D., president and CEO since 2003, was the founder, chief executive officer, and chairman of the board of Neose Technologies, Inc. Eric Sandquist, chief business officer, held senior leadership roles at Merck where he commercialized products in the United States and Europe. David Zopf, M.D., chief scientific officer, was the executive vice president and chief scientific officer of Neose. Nancy Jean Barnabei, chief financial officer, was formerly the vice president of finance, treasurer and chief financial officer for Locus Pharmaceuticals. Elliot Morales, vice president of operations, was previously a vice president of project management and analytical operations with Neose Technologies. Clayton Buck, Ph.D., director of R&D, was the acting director and CEO of the Wistar Institute.



Why is Immune Control's technology an important potential medical breakthrough?

Autoimmune diseases are caused by inappropriately activated immune cells. Traditional therapies are typically directed toward the symptoms, not the immune cells that are the underlying problem. Current autoimmune therapies are thus merely palliative. Hematologic cancer therapies, such as chemotherapy or radiation often damage all dividing cells. Organ transplant therapies broadly suppress the entire immune, impair immune system defenses, and increase the risk of infection.

Immune Control's technology target only the inappropriately activated immune cells, without affecting the non-activated cells that compromise the vast majority of the immune system. In this way, the root cause of these conditions can be addressed without broad, indiscriminant injury to the rest of the immune system.

FINANCING


Immune Control is a venture-backed, privately-held company. In June 2005, Immune Control closed an \$11.3 million series A financing in which four venture capital firms participated: Domain Associates; BioAdvance Venture Fund/Quaker BioVentures; New Spring Capital; and, Anthem Capital Management. An additional \$6 million was raised through existing investors in 2008.

INTELLECTUAL PROPERTY

Immune Control aggressively pursues worldwide patent protection for its technologies.

Currently, we own or license exclusively eight patents and patent applications that are directed toward the use of any serotonergic compound, including our new chemical entities, to treat immune disorders.

PIPELINE



PARTNERING OPPORTUNITIES

Immune Control is interested in partnering its development programs. We are currently applying our breakthrough technology that employs a new mechanism of action to treat autoimmune diseases and hematologic cancer. These are large markets with significant unmet needs, and with the potential for priority FDA review.